ACRO BIOMEDICAL CO., LTD. (ACBM) Form 10-Q — Aug 13, 2026
Acro Biomedical Co., Ltd. filed its 10-Q for the quarter ended June 30, 2026 with substantial doubt about its ability to continue as a going concern. The Nevada shell company held just $3,648 in cash and total assets, carried $448,437 in total liabilities, and reported a stockholders' deficit of $444,789. It has generated no revenue since December 31, 2022 and has no product orders.
Key figures
- Eps
- -0.00
- Revenue
- 0
- Total Assets
- 3648
- Cash Position
- 3648
- Shares Outstanding
- 60042000
- Total liabilities
- 448437
- Owed to former ceo
- 1100
- Imputed interest rate
- 4%
- Due to related parties
- 385387
- Liability forgiveness gain
- 20000
- Working capital deficiency
- 444789
- Due to minority stockholder
- 384287
- Operating expenses six months
- 77825
- Advances from minority stockholder
- 59875
- Related party interest expense six months
- 7305
AI analysis
Red flags8 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.